Intellectual Property Engineer - Patent
About the job
- Have significant initial experience in the pharmaceutical industry in a Patent Engineer position.
- Hold dual training in science and law.
- Hold a CEIPI patent diploma; qualification as a European Patent Attorney is ideally preferred.
- Define the intellectual-property issues associated with major projects by participating in project and product meetings, particularly with the PPMO, Medical, Regulatory, Industrial, DOI, and DOF departments.
- Monitor internal development and research results, assess those results and the opportunity to file patent applications, and work with external intellectual-property firms on drafting and prosecuting applications before the various patent offices.
- List and verify the files associated with each project or product, including patents, trademarks, designs and models, domain names, secret technical files, and contracts.
- Defend LFB's industrial-property rights and develop response strategies for oppositions or invalidation actions against LFB intellectual-property rights in close collaboration with external intellectual-property firms and internal LFB teams.
- Ensure freedom to operate for LFB projects and products, implement and monitor third-party rights, and, where appropriate, initiate opposition or invalidation actions before the relevant offices or courts.
- Provide intellectual-property advice during due diligence, on contractual matters, and in technology-transfer processes and the implementation of inbound and outbound licenses.
- Raise awareness of intellectual-property issues among relevant LFB personnel, including through training.
About the company
LFB is a French biopharmaceutical company that develops and manufactures medicines from plasma and biotech products. It collects plasma, fractionates it into medicines, and also produces recombinant proteins for rare diseases in immunology and hemostasis, sold in many countries. It stands out because it started as a state-initiated public health mission and remains state-owned with the French State as sole shareholder, plus vertical integration through acquisitions of plasma collection firms. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharma player.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Courcebœufs, France
Founded
1994
Get referred to LFB
See people who can refer or advise you
Simplify's Take
What believers are saying
- Arras released first medicines in 2025, proving commercialization after heavy capital spending.
- LFB signed a 2026 collaboration with Sartorius to accelerate client programs and GMP manufacturing.
- France 2030 funding and the 2026 Alès expansion add capacity and roughly fifty jobs.
What critics are saying
- EFS must raise plasma collections to 1.4 million liters by 2028 or Arras underutilizes.
- LFB BIOMANUFACTURING still depends on Sartorius for cell line development, limiting full-stack control.
- A single French industrial base creates existential exposure to contamination, recalls, or regulatory shutdowns.
What makes LFB unique
- French state-owned sole domestic plasma fractionator anchors national medicine supply.
- Arras plant, authorized in 2025, centralizes production and triples plasma-derived capacity.
- Europlasma and Amber Plasma give LFB 24 Central European collection centers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- 401(k) Retirement Plan
- Remote Work Options
- Unlimited Paid Time Off
- Flexible Work Hours
- Paid Vacation
- Hybrid Work Options
- Wellness Program
- Mental Health Support
- Phone/Internet Stipend
- Home Office Stipend
- Stock Options